Survey of prodromal symptoms of Parkinson’s disease in Japan
Objective: To reveal prodromal symptoms at a public seminar for PD via questionnaires. Background: How to select subjects with PD for disease modify therapy in…Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease
Objective: 1) To determine serum urate and homocysteine concentration at baseline, 18 and 36 months in control and PD participants. 2) To determine if urate…Comparison of Test Your Memory (TYM) and Montreal Cognitive Assessment (MoCA) measures in Parkinson’s disease
Objective: We sought to determine: a) the ability of TYM to discriminate between PD patients with and without cognitive deficits b) equivalence between MoCA scores…Neuro-cognitive domain related to conversion of Parkinson’s disease dementia
Objective: To identify neurocognitive domain and mild cognitive impairment (MCI) subtype associated with conversion from non-demented patients with Parkinson's disease (PD) and PD-MCI to dementia…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…
- « Previous Page
- 1
- …
- 34
- 35
- 36